Search

Displaying results 1521 - 1530 of 7498 in total
  1. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). … [L56127] PBC is a rare, chronic autoimmune liver disease characterized by the destruction of small bile ducts, leading to cholestasis and the systemic accumulation of bile acids, which are hypothesized

  2. Drug

    Amsacrine

    go.drugbank.com/drugs/DB00276
    ApprovedInvestigationalWithdrawn

    It produces consistent but acceptable myelosuppression and cardiotoxic effects. … It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors.

  3. Drug

    N-acetyltyrosine

    go.drugbank.com/drugs/DB11102
    ApprovedInvestigational

    N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. [DB00135] is a non-essential amino acid with a polar side group. … N-acetyltyrosine is administered as parenteral nutrition or intravenous infusion due to its enhanced solubility compared to tyrosine [A32652].

    Synonyms: N-acetyltyrosin, N-acetyltyrosine
  4. Drug

    Voretigene neparvovec

    go.drugbank.com/drugs/DB13932
    ApprovedInvestigational

    [A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095] … It is not pathogenic and it causes a very mild immune response.

  5. Drug

    Insulin glargine

    go.drugbank.com/drugs/DB00047
    ApprovedInvestigational

    cells that the body is no longer able to produce insulin on its own. … [L34964] Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism.

  6. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. … It is an investigational drug under regulatory review by FDA.

  7. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons. … Cyanocobalamin Co-60 is an analog of Vitamin B12 labeled with Co60.

    Synonyms: Cyanocobalamin Co 60, Cyanocobalamin Co-60
  8. Drug

    Zuranolone

    go.drugbank.com/drugs/DB15490
    ApprovedInvestigational

    [A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved treatment for women with postpartum depression. … binding to a non-benzodiazepine site on the receptor.

  9. Drug

    Testosterone undecanoate

    go.drugbank.com/drugs/DB13946
    ApprovedInvestigational

    [L35970] It was developed via fatty acid esterification of testosterone in order to achieve orally administer testosterone. … Testosterone replacement therapy aims to restore the levels of testosterone, thereby improving symptoms and signs of testosterone deficiency.[A246614,L35970]

  10. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.

    Mixtures: Darvocet-N 50, Darvocet-N 100Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome